These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35142966)

  • 1. The Impact of Surveillance Imaging Frequency on the Detection of Distant Disease for Patients with Resected Stage III Melanoma.
    Dieng M; Lord SJ; Turner RM; Nieweg OE; Menzies AM; Saw RPM; Einstein AJ; Emmett L; Thompson JF; Lo SN; Morton RL
    Ann Surg Oncol; 2022 May; 29(5):2871-2881. PubMed ID: 35142966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of surveillance imaging for resected high-risk melanoma.
    Yan MK; Adler NR; Wolfe R; Pan Y; Chamberlain A; Kelly J; Yap K; Voskoboynik M; Haydon A; Shackleton M; Mar VJ
    Asia Pac J Clin Oncol; 2023 Aug; 19(4):566-573. PubMed ID: 36540019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of Long-Term CT and PET/CT Surveillance for Detection of Distant Recurrence in Patients with Resected Stage IIIA-D Melanoma.
    Turner RM; Dieng M; Khanna N; Nguyen M; Zeng J; Nijhuis AAG; Nieweg OE; Einstein AJ; Emmett L; Lord SJ; Menzies AM; Thompson JF; Saw RPM; Morton RL
    Ann Surg Oncol; 2021 Aug; 28(8):4561-4569. PubMed ID: 33393039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PET/CT surveillance detects asymptomatic recurrences in stage IIIB and IIIC melanoma patients: a prospective cohort study.
    Madu MF; Timmerman P; Wouters MWJM; van der Hiel B; van der Hage JA; van Akkooi ACJ
    Melanoma Res; 2017 Jun; 27(3):251-257. PubMed ID: 28225434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of PET/CT Surveillance Schedules to Detect Distant Recurrence of Resected Stage III Melanoma.
    Dieng M; Turner RM; Lord SJ; Einstein AJ; Menzies AM; Saw RPM; Nieweg OE; Thompson JF; Morton RL
    Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between the use of surveillance PET/CT and the detection of potentially salvageable occult recurrences among patients with resected high-risk melanoma.
    Leon-Ferre RA; Kottschade LA; Block MS; McWilliams RR; Dronca RS; Creagan ET; Allred JB; Lowe VJ; Markovic SN
    Melanoma Res; 2017 Aug; 27(4):335-341. PubMed ID: 28296712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Earlier Recurrence Detection Using Routine FDG PET-CT Scans in Surveillance of Stage IIB to IIID Melanoma: A National Cohort Study of 1480 Patients.
    Helvind NM; Weitemeyer MB; Chakera AH; Hendel HW; Ellebæk E; Svane IM; Kjærskov MW; Bojesen S; Skyum H; Petersen SK; Bastholt L; Johansen C; Bidstrup PE; Hölmich LR
    Ann Surg Oncol; 2023 Apr; 30(4):2377-2388. PubMed ID: 36752970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surveillance strategies in the follow-up of melanoma patients: too much or not enough?
    Kurtz J; Beasley GM; Agnese D; Kendra K; Olencki TE; Terando A; Howard JH
    J Surg Res; 2017 Jun; 214():32-37. PubMed ID: 28624057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. False-Positive Results and Incidental Findings with Annual CT or PET/CT Surveillance in Asymptomatic Patients with Resected Stage III Melanoma.
    Nijhuis AAG; Dieng M; Khanna N; Lord SJ; Dalton J; Menzies AM; Turner RM; Allen J; Saw RPM; Nieweg OE; Thompson JF; Morton RL
    Ann Surg Oncol; 2019 Jun; 26(6):1860-1868. PubMed ID: 30911946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of PET/CT surveillance imaging to detect systemic recurrence in resected stage III melanoma: study protocol.
    Dieng M; Khanna N; Nguyen MTH; Turner R; Lord SJ; Menzies AM; Allen J; Saw R; Nieweg OE; Thompson J; Morton RL
    BMJ Open; 2020 Nov; 10(11):e037857. PubMed ID: 33154047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The utility of initial staging PET-CT as a baseline scan for surveillance imaging in stage II and III melanoma.
    Ravichandran S; Nath N; Jones DC; Li G; Suresh V; Brys AK; Hanks BA; Beasley GM; Salama AKS; Howard BA; Mosca PJ
    Surg Oncol; 2020 Dec; 35():533-539. PubMed ID: 33161362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Recurrence in Completely Resected IIIB and IIIC Melanoma Warrants Restaging Prior to Adjuvant Therapy.
    Bloemendal M; van Willigen WW; Bol KF; Boers-Sonderen MJ; Bonenkamp JJ; Werner JEM; Aarntzen EHJG; Koornstra RHT; de Groot JWB; de Vries IJM; van der Hoeven JJM; Gerritsen WR; de Wilt JHW
    Ann Surg Oncol; 2019 Nov; 26(12):3945-3952. PubMed ID: 30830540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of Surveillance PET/CT on Detection of Early Recurrence After Definitive Radiation in Stage III Non-small-cell Lung Cancer.
    Reddy JP; Tang C; Shih T; Kim B; Kim C; Nguyen QN; Welsh J; Benveniste M; Zhang J; Liao Z; Gomez DR
    Clin Lung Cancer; 2017 Mar; 18(2):141-148. PubMed ID: 27913215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole body PET/CT in the follow-up of asymptomatic patients with stage IIB-IIIB cutaneous melanoma
    Koskivuo I; Kemppainen J; Giordano S; Seppänen M; Veräjänkorva E; Vihinen P; Minn H
    Acta Oncol; 2016 Nov; 55(11):1355-1359. PubMed ID: 27553064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is surveillance imaging effective for detecting surgically treatable recurrences in patients with melanoma? A comparative analysis of stage-specific surveillance strategies.
    Rueth NM; Xing Y; Chiang YJ; Cromwell KD; Ross MI; Lee JE; Gershenwald JE; Royal RE; Cormier JN
    Ann Surg; 2014 Jun; 259(6):1215-22. PubMed ID: 24096759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma.
    Beasley GM; Parsons C; Broadwater G; Selim MA; Marzban S; Abernethy AP; Salama AK; Eikman EA; Wong T; Zager JS; Tyler DS
    Ann Surg; 2012 Aug; 256(2):350-6. PubMed ID: 22691370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Routine PET-CT scans provide early and accurate recurrence detection in asymptomatic stage IIB-III melanoma patients.
    Helvind NM; Aros Mardones CA; Hölmich LR; Hendel HW; Bidstrup PE; Sørensen JA; Chakera AH
    Eur J Surg Oncol; 2021 Dec; 47(12):3020-3027. PubMed ID: 34120809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging Intensity and Survival Outcomes in High-Risk Resected Melanoma Treated by Systemic Therapy at Recurrence.
    Ibrahim AM; Le May M; Bossé D; Marginean H; Song X; Nessim C; Ong M
    Ann Surg Oncol; 2020 Oct; 27(10):3683-3691. PubMed ID: 32363515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of imaging strategy for an intensive follow-up of patients with American Joint Committee on Cancer stage IIB, IIC and III malignant melanoma.
    Podlipnik S; Moreno-Ramírez D; Carrera C; Barreiro A; Manubens E; Ferrandiz-Pulido L; Sánchez M; Vidal-Sicart S; Malvehy J; Puig S
    Br J Dermatol; 2019 May; 180(5):1190-1197. PubMed ID: 29876940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrence patterns in patients with Stage II melanoma: The evolving role of routine imaging for surveillance.
    Bleicher J; Swords DS; Mali ME; McGuire L; Pahlkotter MK; Asare EA; Bowles TL; Hyngstrom JR
    J Surg Oncol; 2020 Dec; 122(8):1770-1777. PubMed ID: 33098702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.